Search results for "Adverse Reactions"

showing 10 items of 110 documents

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

2015

PD-1 checkpoint inhibitors are associated with a specific spectrum of immune-related adverse events. This spectrum is different from toxicities known for kinase inhibitors or cytotoxic drugs. Since PD-1 directed therapies show effectivity in an increasing number of malignant diseases, their clinical usage will increase rapidly. Therefore clinicians from different specialities such as medical oncology, internal medicine, family doctors and emergency unit staff should be aware of the adverse effects of PD-1 checkpoint inhibitors to avoid delays in diagnosis and treatment. Based on pooled data from pivotal trials as reported by the European Medicines Agency, the present paper reviews incidence…

medicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorMedizinAntineoplastic AgentsPembrolizumabAntibodies Monoclonal HumanizedB7-H1 Antigen03 medical and health sciences0302 clinical medicineRefractoryMonitoring ImmunologicNeoplasmsmedicineEndocrine systemHumansRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineAdverse effectbusiness.industryAntibodies MonoclonalDisease ManagementGeneral MedicineImmunotherapymedicine.diseaseEarly DiagnosisNivolumabOncologyMethylprednisolone030220 oncology & carcinogenesisImmunologyNivolumabbusinessAdverse drug reactionImmunosuppressive Agentsmedicine.drugCancer treatment reviews
researchProduct

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

2021

Introduction Immune checkpoint inhibitors (ICIs) are widely used in the treatment of many cancers as they improve clinical outcomes. However, ICIs have also been associated with the development of immune-related adverse drug reactions (ADRs). Among immune-related ADRs, cardiac immune-related ADRs are rare, but also associated with high mortality rates. Objective The objective of this study was to evaluate the occurrence of cardiac ADRs reported with ICIs in the European spontaneous reporting system. Methods We retrieved individual case safety reports on ICI-induced cardiac ADRs from the website of suspected ADR (www.adrreports.eu) of the European pharmacovigilance database (Eudravigilance).…

medicine.medical_specialtyDurvalumabDrug-Related Side Effects and Adverse ReactionsIpilimumabPembrolizumabToxicology030226 pharmacology & pharmacyPharmacovigilance03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinePharmacovigilancemedicineHumansPharmacology (medical)Original Research Article030212 general & internal medicineMyocardial infarctionImmune Checkpoint InhibitorsPharmacologybusiness.industryOdds ratiomedicine.diseaseIpilimumabNivolumabNivolumabbusinessmedicine.drugDrug Safety
researchProduct

Iatrogenic pulmonary lesions.

2018

Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eo…

medicine.medical_specialtyPathologyDrug-Related Side Effects and Adverse ReactionsPolymersIatrogenic DiseaseAmiodaroneAntineoplastic Agents030204 cardiovascular system & hematologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineEarly Medical InterventionmedicineEosinophilic pneumoniaHumansImmunologic FactorsIntensive care medicineDiffuse alveolar damageAdverse effectLungLungRadiotherapybusiness.industryInterstitial lung diseasePulmonary edemamedicine.diseasemedicine.anatomical_structureEquipment and SuppliesNitrofurantoin030220 oncology & carcinogenesisPulmonary hemorrhagebusinessLung Diseases InterstitialAnti-Arrhythmia AgentsHydrophobic and Hydrophilic InteractionsHypersensitivity pneumonitisSeminars in diagnostic pathology
researchProduct

Chelation treatment in sickle-cell-anaemia: much ado about nothing?

2011

Summary Blood transfusions may prevent and treat serious complications related to sickle-cell disease (SCD) when performed according to specific guidelines. However, blood transfusion requirements in SCD inevitably lead to increased body iron burden. An adequate chelation treatment may prevent complications and reduce morbidity and mortality. This review evaluates the effectiveness, safety and costs of chelation treatment. The included trials were examined according to the recommendations of the American College of Cardiology (ACC) and the American Heart Association (AHA). Overall, 14 trials and a total of 502 patients with SCD were included in this review. Deferoxamine alone (s.c. or i.v.)…

medicine.medical_specialtyPediatricsBlood transfusionDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentAnemia Sickle CellDiseaseIron Chelating Agentslaw.inventionBody ironchemistry.chemical_compoundRandomized controlled triallawmedicineHumansChelationIntensive care medicinebusiness.industryDeferasiroxHematologyChelation TherapyDeferoxamineTreatment OutcomechemistryCosts and Cost AnalysisDeferipronebusinessChelation treatment sickle-cell-diseasemedicine.drug
researchProduct

[Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011)].

2014

Introduction: In 2009, two cases of seizures in adolescents following quadrivalent human papillomavirus vaccine (qHPV) administration generated important media attention, and adversely affected public trust in this vaccine. Our objectives were to describe suspected adverse reactions (SARs) reported to the Pharmacovigilance Centre in the Valencian Community (PCVC) after administration of HPV vaccine, and to compare reporting rates of syncope and seizures following this vaccine with those of other vaccines administered to girls aged 13–15 years. Materials and methods: Descriptive study of SARs reported following administration of this vaccine to the PCVC between 2007 and 2011. Results: The cl…

medicine.medical_specialtyPediatricsHuman papillomavirusTime FactorsAdolescentVirus del papiloma humanoVaccines AdministeredHuman papillomavirus vaccinePediatricsRJ1-570Valencian communitySyncopeReporting ratePharmacovigilanceHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18SeizuresManagement of Technology and InnovationPharmacovigilanceMedicineHumansRetrospective StudiesbiologyVacunabusiness.industryReacción adversaSyncope (genus)PharmacovigitanceTasa de notificaciónbiology.organism_classificationSurgeryVaccinationFarmacovigilanciaSpainFemalebusinessAdverse reactionsVaccineAnales de pediatria (Barcelona, Spain : 2003)
researchProduct

Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists

2022

The recent therapeutic progress in multiple myeloma (MM) has led to the introduction of novel and highly potent drug classes. Daratumumab was the first CD38-targeting antibody showing to be effective and safe in MM patients as monotherapy and in combination regimens, which led to its rapid implementation in clinical practice. Considering that treatment discontinuation for drug-related adverse events can impact patients’ quality of life and outcomes, the treatment decision should consider different factors and be weighted for each patient individually. Here, we aimed to guide clinicians using daratumumab treatment for MM by addressing practical real-world considerations based on an expert pa…

multiple myelomaCancer ResearchOncologydelivery of health careNeoplasms. Tumors. Oncology. Including cancer and carcinogensadverse reactionsdaratumumabdrug-related side effectsRC254-282Frontiers in Oncology
researchProduct

Exercise medicine for cancer cachexia: targeted exercise to counteract mechanisms and treatment side effects.

2022

Abstract Purpose Cancer-induced muscle wasting (i.e., cancer cachexia, CC) is a common and devastating syndrome that results in the death of more than 1 in 5 patients. Although primarily a result of elevated inflammation, there are multiple mechanisms that complement and amplify one another. Research on the use of exercise to manage CC is still limited, while exercise for CC management has been recently discouraged. Moreover, there is a lack of understanding that exercise is not a single medicine, but mode, type, dosage, and timing (exercise prescription) have distinct health outcomes. The purpose of this review was to examine the effects of these modes and subtypes to identify the most opt…

muscle atrophyInflammationtumorCancer ResearchCachexiaexerciseDrug-Related Side Effects and Adverse Reactionslihaskatomuscle wastingGeneral MedicineMuscular AtrophylihasmassaOncologyinflammationNeoplasmsHumanssyöpätauditkakeksiavoimaharjoittelulihaskuntoMuscle SkeletalExercisecancer cachexiaJournal of cancer research and clinical oncology
researchProduct

Management of Statin Intolerance in 2018: Still More Questions Than Answers.

2018

Statin therapy is generally well tolerated and very effective in the prevention and treatment of cardiovascular disease, regardless of cholesterol levels; however, it can be associated with various adverse events (myalgia, myopathy, rhabdomyolysis, and diabetes mellitus, among others). Patients frequently discontinue statin therapy without medical advice because of perceived side effects and consequently increase their risk for cardiovascular events. In patients with statin intolerance, it may be advisable to change the dose, switch to a different statin, or try an alternate-day regimen. If intolerance is associated with all statins—even at the lowest dose—non-statin drugs and certain nutra…

myalgiamedicine.medical_specialtyStatinDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classDiseaseReview Article030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePharmacotherapyMedical adviceDiabetes mellitusCardiovascular DiseasemedicineHumansPharmacology (medical)030212 general & internal medicinecardiovascular diseasesAdverse effectIntensive care medicineDietary SupplementHypolipidemic AgentsHypolipidemic Agentbusiness.industrynutritional and metabolic diseasesDisease ManagementGeneral MedicineCholesterol LDLmedicine.diseaseRegimenCardiovascular DiseasesDietary Supplementslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitormedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDrug-Related Side Effects and Adverse ReactionHumanAmerican journal of cardiovascular drugs : drugs, devices, and other interventions
researchProduct

Methylprednisolone-induced hepatotoxicity in a 16-year-old girl with multiple sclerosis.

2018

Multiple sclerosis (MS) is a chronic inflammatory disease with demyelination of the central nervous system. High-dosage corticosteroids are the first-line therapy in the acute relapsing of MS. We report a case of severe high-dose methylprednisolone-induced acute hepatitis in a patient with a new diagnosis of MS. A 16-year-old girl was admitted for urticaria, angioedema, nausea and vomiting a month later she had been diagnosed with MS and treated with high-dosage methylprednisolone. Laboratory investigations showed hepatic insufficiency with grossly elevated liver enzymes. A liver biopsy showed focal centrilobular hepatocyte necrosis with interface hepatitis. Methylprednisolone-induced hepat…

paediatrics (drugs And Medicines)safetymedicine.medical_specialtyMultiple SclerosisAdolescentNauseaAnti-Inflammatory AgentsGastroenterologyMethylprednisoloneDiagnosis Differential03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineHumansunwanted effects/adverse reactionsGlucocorticoidsmedicine.diagnostic_testAngioedemabusiness.industryMultiple sclerosisGeneral Medicinemedicine.diseaseMethylprednisolonePulse Therapy DrugLiver biopsyVomitingSettore MED/26 - Neurologia030211 gastroenterology & hepatologyFemaleDifferential diagnosismedicine.symptomChemical and Drug Induced Liver Injuryliver diseasebusiness030217 neurology & neurosurgerymedicine.drugFindings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse EffectBMJ case reports
researchProduct

Could PD-1/PDL1 immune checkpoints be linked to HLA signature?

2019

The outstanding clinical expansion of monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PDL-1) (atezolizumab, avelumab and durvalumab) has received an increasing level of interest regarding immunotherapy and multidrug combinations, for the treatment of a number of common human malignancies. Some patients treated with these agents receive remarkable benefits in term of quality of life, progression-free (PFS) and overall survival (OS). However, a significant percentage of these patients experience immune-related adverse events (irAEs), while others present with an ultra-rapid disease progression, defined as hyperprogressio…

vDrug-Related Side Effects and Adverse ReactionsProgrammed Cell Death 1 ReceptorImmunologyAntibodies Monoclon alHuman leukocyte antigenB7-H1 AntigenImmune systemHLA AntigensirAENeoplasmsHumansImmunology and AllergyMedicinePD-1/PDL-1-blockadebusiness.industryAntibodies MonoclonalBiomarkerProgrammed Cell Death 1 ReceptorSignature (logic)HaplotypesOncologyImmunologyoutcomeImmunotherapyHLA alleleDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersB7-H1 AntigenImmunotherapy
researchProduct